Generalized Myasthenia Gravis Clinical Trial
Official title:
An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05514873 -
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
|
Phase 3 | |
| Completed |
NCT04124965 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT04833894 -
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04963270 -
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Active, not recruiting |
NCT02950155 -
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03315130 -
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
|
Phase 2 | |
| Recruiting |
NCT05556096 -
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03920293 -
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
| Not yet recruiting |
NCT06193889 -
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT03770403 -
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
|
Phase 3 | |
| Completed |
NCT03971422 -
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05403541 -
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05644561 -
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
|
Phase 3 | |
| Completed |
NCT00515450 -
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT06064695 -
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
|
N/A | |
| Withdrawn |
NCT04982289 -
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT04735432 -
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT04650854 -
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
|
Phase 3 | |
| Active, not recruiting |
NCT05218096 -
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
|
Phase 2 | |
| Active, not recruiting |
NCT04225871 -
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
|
Phase 3 |